Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Investigation of IRAK4 Inhibition to Mitigate the Impact of COVID-19 in Severe SARS-CoV-2 (I-RAMIC)

Next Previous
X
Search
Trial Profile

Investigation of IRAK4 Inhibition to Mitigate the Impact of COVID-19 in Severe SARS-CoV-2 (I-RAMIC)

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 28 Oct 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Zimlovisertib (Primary) ; Zimlovisertib (Primary)
  • Indications COVID-19 respiratory infection; SARS-CoV-2 acute respiratory disease
  • Focus Therapeutic Use
  • Acronyms I-RAMIC

    • Most Recent Events

    • 18 Oct 2021 Status changed from active, no longer recruiting to discontinued (Study terminated due to lack of enrollment reflecting the decrease in number of COVID infections. There were no safety and/or efficacy concerns involved in the decision to stop enrollment).
    • 13 Oct 2021 Status changed from recruiting to active, no longer recruiting.
    • 18 May 2021 Planned End Date changed from 31 Mar 2021 to 31 Dec 2021.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top